<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pulmonary Langerhans cell histiocytosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pulmonary Langerhans cell histiocytosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pulmonary Langerhans cell histiocytosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Newburger, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pulmonary Langerhans cell histiocytosis (PLCH), previously called eosinophilic granuloma of the lung, pulmonary Langerhans cell granulomatosis, and pulmonary histiocytosis X, is an uncommon cystic interstitial lung disease that primarily affects young adults [<a href="#rid1">1-5</a>]. It is caused by a disorder of myeloid dendritic cells. No occupational or geographic predisposition has been reported, but nearly all affected individuals have a history of current or prior cigarette smoking. Thus, tobacco smoke is thought to be a contributing factor.</p><p>The pathogenesis, clinical presentation, diagnosis, and treatment of PLCH will be reviewed here. A general review of Langerhans cell histiocytosis, including the more common, extrapulmonary manifestations of this disorder, is presented separately. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a> and  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis"</a>.)</p><p class="headingAnchor" id="H1191578368"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The exact incidence and prevalence of PLCH are unknown, but it is uncommon [<a href="#rid4">4-8</a>]. PLCH is estimated to account for 3 to 5 percent of adult diffuse parenchymal lung disease [<a href="#rid7">7,8</a>]. Frequency depends on the prevalence of cigarette smoking in the population, as more than 90 percent of patients with PLCH are cigarette smokers [<a href="#rid3">3-5</a>]. White individuals are affected more commonly than Black individuals. </p><p>The rarity of the diagnosis is highlighted by a study from Japan, in which the prevalence estimates were 0.27 per 100,000 in males and 0.07 per 100,000 among females [<a href="#rid6">6</a>]. Similarly, a review from a specialty lung disease center in Italy found 40 cases over 10 years [<a href="#rid5">5</a>].</p><p>The age of onset peaks between 20 and 40 years of age [<a href="#rid3">3</a>]. In general, there is an equal distribution between males and females, though females tend to present at an older age [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>The term "histiocyte" refers to large white blood cells resident in tissues and includes Langerhans cells, monocytes/macrophages, and dermal/interstitial dendritic cells. The pathologic cell type in PLCH is a dendritic cell of the monocyte-macrophage line that resembles cutaneous Langerhans cells [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Histiocytic disorders'</a>.)</p><p>Based on accumulating evidence of somatic oncogenic mutations in pulmonary CD1a dendritic cells, PLCH is thought to be an inflammatory myeloid neoplasm [<a href="#rid10">10,11</a>]. In LCH, both the CD1a dendritic cells and their progenitor cells, CD34+ mononuclear cells, carry somatic mutations in the mitogen-activated protein kinase (MAPK) pathway, particularly the <em>BRAF</em> genes discussed below [<a href="#rid7">7,12</a>]. (See <a class="local">'Somatic mutations in MAPK pathway'</a> below and  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Pathophysiology'</a>.) </p><p>Langerhans cells are normally found in low numbers in the dermis, the reticuloendothelial system, the lung, and the pleura. They can be present in increased numbers in the lung in association with cigarette smoking in otherwise healthy individuals and can also be seen in other pulmonary disorders, such as idiopathic pulmonary fibrosis [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/d/html/4300.html" rel="external">"Pathogenesis of idiopathic pulmonary fibrosis"</a>.)</p><p class="headingAnchor" id="H4175887749"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>In PLCH, the Langerhans-like cells, which express CD1a, S100 protein, and langerin (CD207), are characteristically found in clusters and in significantly greater numbers than in other lung diseases, although quantitative guidelines for the diagnosis of PLCH have not been established. </p><p>Early inflammatory lesions of PLCH surround the smaller bronchioles and usually contain an admixture of eosinophils, lymphocytes, and neutrophils  (<a class="graphic graphic_picture graphicRef55413" href="/d/graphic/55413.html" rel="external">picture 1</a>) and are associated with destruction of the bronchiolar wall and adjacent lung parenchyma [<a href="#rid9">9,15</a>]. Since eosinophils are not a prominent part of the pathology and the lesions can be devoid of eosinophils, the outdated term “eosinophilic granuloma” is a misnomer. The inflammatory lesions of PLCH can also involve pulmonary arterioles and venules  (<a class="graphic graphic_picture graphicRef58695" href="/d/graphic/58695.html" rel="external">picture 2</a>) [<a href="#rid16">16</a>].</p><p>There is often a predominance of disease in the mid to upper zones of the lung, in contrast with the typical lower zone predominance of idiopathic pulmonary fibrosis. Lesions frequently extend widely into the parenchyma of the lung surrounding the bronchovascular structures, producing the so-called <strong>stellate lesions</strong> that are characteristic of this disorder  (<a class="graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661" href="/d/graphic/52774.html" rel="external">picture 3A-C</a>). </p><p>Interstitial fibrosis and cysts develop with advancing disease; the mechanism for cyst formation is unknown, but may be the end result of progressive destruction of bronchiolar and alveolar walls [<a href="#rid7">7</a>].</p><p>Three other pathologic features that may be seen in PLCH reflect, at least in part, exposure to tobacco smoke [<a href="#rid7">7,16,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pseudo-desquamative interstitial pneumonia (DIP), characterized by the accumulation of alveolar macrophages in the pulmonary parenchyma in between the typical lesions containing Langerhans-like cells. (See  <a class="medical medical_review" href="/d/html/4302.html" rel="external">"Idiopathic interstitial pneumonias: Classification and pathology", section on 'Desquamative interstitial pneumonia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory ("smokers") bronchiolitis, characterized by pigmented macrophages filling the lumen of bronchioles and the surrounding alveolar spaces. (See  <a class="medical medical_review" href="/d/html/4319.html" rel="external">"Respiratory bronchiolitis-associated interstitial lung disease", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intraluminal fibrosis, characterized by mural incorporation, alveolar obliteration, and intraluminal buds. This finding supports the hypothesis that intraluminal fibrosis is a mechanism for alveolar collapse with progression to interstitial fibrosis and lung remodeling [<a href="#rid18">18</a>].</p><p></p><p>On electron microscopy, which is rarely performed, Langerhans-like cells are identified by classic pentalaminar cytoplasmic inclusions or Birbeck granules (previously called X-bodies  (<a class="graphic graphic_picture graphicRef60620" href="/d/graphic/60620.html" rel="external">picture 4</a>)), of which langerin (CD207) is a component.</p><p class="headingAnchor" id="H2021589936"><span class="h2">Somatic mutations in MAPK pathway</span><span class="headingEndMark"> — </span>Somatic mutations that activate the mitogen-activated protein kinase (MAPK) pathway are present in virtually all cases of LCH and PLCH [<a href="#rid11">11,19</a>]. In both LCH and PLCH, the most common variants are <em>BRAF</em> V600E (50 percent) and MAPK2K1 (25 percent) genes encoding protein kinases, but numerous others have been described [<a href="#rid11">11</a>]. These variants lead to constitutive activation of MAPK signaling and downstream activation of transcription factors that promote cell proliferation and survival [<a href="#rid10">10,11,20</a>]. The individual variants do not appear to have a differential effect on the clinical presentation or prognosis of PLCH [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Pathophysiology'</a>.) </p><p>Sequencing studies suggest that PLCH involves clonal processes associated with these variants in MAPK pathway genes [<a href="#rid11">11,20</a>]. Somatic <em>BRAF</em> V600E mutations have been found in a number of benign and malignant tumors and are thought to contribute to the development of cancer. Both <em>BRAF</em> and <em>NRAS</em> mutations have been found in PLCH lesions and in circulating Langerhans-like CD1a<sup>+</sup> cells [<a href="#rid21">21,22</a>]. The characteristics of <em>BRAF</em> mutations associated with lung cancer are described separately. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'BRAF mutations'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Role of cigarette smoking</span><span class="headingEndMark"> — </span>The near universal association of PLCH with tobacco smoking strongly implies a causative role [<a href="#rid17">17,23,24</a>]. In contrast, there does <strong>not</strong> appear to be an association of smoking with extrapulmonary LCH. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p>Various mechanisms by which smoking might contribute to the pathogenesis of PLCH have been hypothesized, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoke promotes accumulation of nonneoplastic CD1a dendritic cells around airways and may also promote maintenance of CD1a cells with oncogenic mutations [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cigarette smoking may have an anti-apoptotic effect that contributes to accumulation of CD1a cells in PLCH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is unclear whether inflammation from cigarette smoking contributes to the acquisition of oncogenic mutations by Langerhans-like cells in the lungs [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H646720268"><span class="h2">Abnormalities in immune function</span><span class="headingEndMark"> — </span>Abnormalities in immune function are reported in association with PLCH [<a href="#rid7">7</a>], including:</p><p class="bulletIndent1"><span class="glyph">●</span>A nonspecific increase in IgG in bronchoalveolar lavage fluid</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased granulocyte-monocyte colony stimulating factor (GM-CSF), transforming growth factor (TGF)-beta, and tumor necrosis factor (TNF)-alpha in areas of PLCH, based on immunohistochemistry</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in T-cell function</p><p></p><p>The role of these changes in the pathophysiology of PLCH is not known; they may represent nonspecific generalized activation of immune effector cells [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Most cases of PLCH occur in young adults between 20 and 40 years of age, but PLCH is described among younger and older individuals  (<a class="graphic graphic_figure graphicRef69932" href="/d/graphic/69932.html" rel="external">figure 1</a>) [<a href="#rid25">25-29</a>]. The duration of illness is usually less than one year prior to diagnosis [<a href="#rid1">1,2,30,31</a>]. </p><p class="headingAnchor" id="H1754166305"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Patients with PLCH present to medical attention in one of several ways [<a href="#rid7">7,32,33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>With abnormalities incidentally detected on chest radiographs</p><p class="bulletIndent1"><span class="glyph">●</span>Following a spontaneous pneumothorax </p><p class="bulletIndent1"><span class="glyph">●</span>With respiratory or constitutional symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>In follow-up to treatment of childhood LCH</p><p></p><p>When patients present with symptoms, the most common symptoms include [<a href="#rid2">2,4,15,27,32,34-37</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonproductive cough (56 to 70 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea (40 to 87 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain, which is frequently pleuritic (10 to 21 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue (approximately 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss (20 to 30 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Fever (15 percent)</p><p></p><p>The physical examination is usually unremarkable, except in cases of pneumothorax or advanced disease. Crackles and digital clubbing are uncommonly found on examination [<a href="#rid7">7,38</a>]. (See  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p class="headingAnchor" id="H1202439089"><span class="h2">Extrapulmonary manifestations</span><span class="headingEndMark"> — </span>Extrapulmonary LCH is noted in approximately 20 percent of reported cases of PLCH at the time of diagnosis [<a href="#rid25">25,29</a>]. Approximately 5 percent of patients with only pulmonary involvement at diagnosis develop extrapulmonary manifestations during follow-up [<a href="#rid29">29</a>]. When present, the following manifestations are most common:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone lesions</strong> – Cystic bone lesions are present in 4 to 17 percent of patients and may be an incidental finding or produce localized pain or a pathologic bone fracture [<a href="#rid3">3,25,29</a>]. Skeletal involvement may precede the more typical pulmonary manifestations, and may be the sole manifestation of LCH. The radiographic pattern on bone films is not diagnostic. In most instances, the lesions are solitary and involve the jaw, vertebra, or flat bones. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diabetes insipidus – </strong>Hypothalamic involvement with LCH causing diabetes insipidus is seen in approximately 5 to 15 percent of patients, and is believed to portend a worse prognosis [<a href="#rid3">3,25,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin lesions</strong> – Skin lesions are reported in &lt;5 percent of adults with PLCH [<a href="#rid25">25,29</a>]. Presentations vary, but brown to purplish papules and eczematoid or seborrhea-like lesions are more common. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Skin and oral mucosa'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The signs and symptoms of PLCH are nonspecific and often mimic other, more common pulmonary diagnoses. However, PLCH should be suspected in patients with upper lung zone cystic or nodular radiographic abnormalities, or a history of recurrent pneumothorax, diabetes insipidus, or bone pain. A current or past history of tobacco smoking or exposure is an important (but not essential) historical feature. (See  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a>.)</p><p>The evaluation is designed to identify characteristic features of PLCH  (<a class="graphic graphic_table graphicRef119828" href="/d/graphic/119828.html" rel="external">table 1</a>), assess the severity of respiratory impairment, and exclude other processes in the differential diagnosis (eg, lymphangioleiomyomatosis, lymphoid interstitial pneumonia, Birt-Hogg-Dubé) (see <a class="local">'Differential diagnosis'</a> below). Approaches to the diagnosis of extrapulmonary LCH, interstitial lung disease, and cystic lung disease  (<a class="graphic graphic_table graphicRef108810" href="/d/graphic/108810.html" rel="external">table 2</a>) are provided separately. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a> and  <a class="medical medical_review" href="/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/d/html/112259.html" rel="external">"Diagnostic approach to the adult with cystic lung disease"</a>.)</p><p class="headingAnchor" id="H3883811358"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>The main role for laboratory testing is to exclude other causes of interstitial or cystic lung disease, as there are no routine laboratory tests that are diagnostic of PLCH. Routine laboratory studies are usually unrevealing, and the peripheral eosinophil count is normal. (See  <a class="medical medical_review" href="/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Laboratory tests'</a> and  <a class="medical medical_review" href="/d/html/112259.html" rel="external">"Diagnostic approach to the adult with cystic lung disease", section on 'Laboratory testing'</a>.)</p><p>Testing for alpha-1 antitrypsin deficiency is appropriate in patients with airflow limitation on pulmonary function tests and when the differentiation between cystic lung disease and bullous emphysema is unclear.</p><p>Patients with symptoms of polyuria and thirst should be evaluated for diabetes insipidus. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Endocrinopathies'</a>.)</p><p>The role of peripheral blood polymerase chain reaction (PCR) testing for the <em>BRAF</em> V600E and other mitogen-activated protein kinase (MAPK; eg, MAPK2K1) mutations has not been determined. (See <a class="local">'Somatic mutations in MAPK pathway'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Most evaluations for PLCH are prompted after a chest radiograph is noted to be abnormal. High-resolution computed tomography (HRCT) of the chest, if classic, can be diagnostic, and therefore should be obtained in all patients suspected of having the disease [<a href="#rid39">39</a>]. The radiographic appearance of PLCH can be very characteristic, if not diagnostic. A combination of the following features is felt to be highly specific for PLCH [<a href="#rid40">40-43</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ill-defined or stellate nodules (2 to 10 mm in size)</p><p class="bulletIndent1"><span class="glyph">●</span>Reticular and nodular opacities</p><p class="bulletIndent1"><span class="glyph">●</span>Upper zone cysts or honeycombing</p><p class="bulletIndent1"><span class="glyph">●</span>Preservation of lung volume</p><p class="bulletIndent1"><span class="glyph">●</span>Costophrenic angle sparing</p><p></p><p>The reticular and nodular opacities are typically seen in the middle to upper lung zones  (<a class="graphic graphic_diagnosticimage graphicRef82197" href="/d/graphic/82197.html" rel="external">image 1</a>). The total lung volume is normal, although both hyperinflation and reduced volume can occur  (<a class="graphic graphic_diagnosticimage graphicRef60751" href="/d/graphic/60751.html" rel="external">image 2</a>) [<a href="#rid28">28,35</a>]. Hilar or mediastinal adenopathy is rare and should prompt consideration of malignancy as a secondary diagnosis. Pleural thickening or effusion is rarely seen in the absence of a previous pneumothorax. Bone lesions can occur in any bone, including the ribs. (See  <a class="medical medical_review" href="/d/html/6979.html" rel="external">"Evaluation of diffuse lung disease by conventional chest radiography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography</strong> – HRCT of the chest is an essential component of the evaluation of suspected PLCH. The combination of multiple cysts and nodules, with a mid to upper zone predominance, and interstitial thickening in a young smoker is so characteristic that it can be diagnostic of PLCH  (<a class="graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698" href="/d/graphic/58182.html" rel="external">image 3A-C</a>) [<a href="#rid41">41,44</a>]. The nodules can be poorly or well defined; cysts are thin-walled, of varying size, and sometimes bizarrely shaped. Honeycombing can be seen in advanced disease. The degree of cyst formation is often under appreciated by routine chest radiography. (See  <a class="medical medical_review" href="/d/html/6988.html" rel="external">"High resolution computed tomography of the lungs", section on 'Langerhans cell histiocytosis'</a>.)</p><p></p><p class="bulletIndent1">Studies of serial chest CT scans suggest a sequence of progression from nodules to cavitating nodules to cystic lesions [<a href="#rid45">45,46</a>]. This progression may explain a number of "spontaneous remissions" reported before the routine use of HRCT. The value of serial lung CT scanning in the routine follow-up of patients has been questioned [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FDG-PET scan</strong> - Fluorodeoxyglucose-positron emission tomography (FDG-PET) scans may show increased uptake in the lungs in patients with PLCH, particularly when obtained early in the course of disease [<a href="#rid48">48</a>], but are generally not helpful in the evaluation of PLCH unless extrapulmonary disease is suspected [<a href="#rid49">49</a>]. In a series of 11 patients with PLCH, five had abnormal FDG uptake in the lungs [<a href="#rid48">48</a>]. Patients with FDG-PET positivity were more likely to have a nodular radiographic pattern, suggesting earlier disease; those with negative FDG-PET scans were more likely to have a cystic pattern and fewer nodules, suggesting later disease. However, FDG-PET does not differentiate between nodules due to PLCH and lung malignancy [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent1">FDG-PET scanning is frequently used to assess disease extent and activity in patients with extrapulmonary LCH [<a href="#rid49">49</a>], but is unlikely to identify unsuspected extrapulmonary disease in patients with PLCH and no extrapulmonary symptoms [<a href="#rid48">48,50</a>]. </p><p></p><p class="headingAnchor" id="H11"><span class="h2">Pulmonary function testing</span><span class="headingEndMark"> — </span>Pulmonary function tests with spirometry, lung volumes, diffusing capacity for carbon monoxide (DLCO), and six-minute walk test (6MWT) are obtained to assess the pattern and severity of respiratory impairment. In general, total lung capacity and expiratory flow rates are well-preserved in PLCH [<a href="#rid15">15,35,51-53</a>]. Predominantly nodular disease is usually associated with normal or restrictive pulmonary function tests, whereas cystic disease is more likely to be associated with abnormal physiologic testing [<a href="#rid46">46</a>]. </p><p>The following abnormalities can be seen:</p><p class="bulletIndent1"><span class="glyph">●</span>Airflow limitation and hyperinflation occur in a minority of patients, typically in patients with more advanced, cystic disease [<a href="#rid27">27,46,47</a>]. Airflow limitation is sometimes reversible, with significant improvement after bronchodilator administration [<a href="#rid13">13,28,35,52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subgroup of patients shows predominantly restrictive disease [<a href="#rid27">27</a>], with reduced total lung volume and increased elastic recoil.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The DLCO is disproportionately reduced, relative to changes in lung volume, in most patients [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulse oxygen saturation (SpO<sub>2</sub>) at rest and with ambulation is generally preferred to measurement of arterial blood gases (ABGs). ABGs obtained at rest usually show a normal alveolar-arterial oxygen difference and a normal carbon dioxide tension (PaCO<sub>2</sub>) and pH and are an insensitive indicator of disease.</p><p></p><p>Patients with PLCH frequently demonstrate a degree of exercise intolerance out of proportion to pulmonary function abnormalities [<a href="#rid35">35,54</a>]. While not necessary in the majority of patients, cardiopulmonary exercise testing (CPET) can be helpful in clarifying that exercise intolerance is indeed due to a respiratory, rather than cardiac, limitation. </p><p>Exercise capacity assessed by CPET is decreased, whether measured by work achieved or oxygen utilization (VO<sub>2</sub>) at maximal exercise. The oxygen pulse at maximal exercise and at anaerobic threshold is reduced in most patients. The maximal ventilatory response is excessive (but not limiting) for the maximal level of work.</p><p>Gas exchange abnormalities, reflected by a rising alveolar-arterial oxygen difference with increasing exercise, are seen in the majority of patients. In most patients, dead space to tidal volume ratio (VD/VT) is either abnormally elevated at rest or fails to decrease with exercise. This abnormality suggests either pathologic or functional involvement of the pulmonary vasculature by the disease process.</p><p class="headingAnchor" id="H13"><span class="h2">Flexible bronchoscopy</span><span class="headingEndMark"> — </span>Flexible bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB) can be helpful to evaluate for other causes of nodular or cystic disease, such as hypersensitivity pneumonitis, infection, lymphangioleiomyomatosis, and lymphoid interstitial pneumonia. (See  <a class="medical medical_review" href="/d/html/4308.html" rel="external">"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"</a> and  <a class="medical medical_review" href="/d/html/112259.html" rel="external">"Diagnostic approach to the adult with cystic lung disease", section on 'Bronchoscopy'</a>.) </p><p>In most cases, the combination of TBLB and BAL, supplemented with the identification cells that express CD-1a and CD207 in tissue and BAL fluid, is highly likely to result in the correct diagnosis [<a href="#rid7">7,55</a>]. However, in advanced disease with extensive fibrosis, the number of CD1a dendritic Langerhans-like cells in tissue specimens and BAL fluid decreases dramatically, making diagnosis difficult regardless of the laboratory methods used. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchoalveolar lavage</strong> – BAL is performed in an area of radiographic abnormality that is amenable to wedging of the bronchoscope. Samples of BAL fluid are sent for cell counts, microbiologic analysis, and cytology with immunostaining for CD1a and CD207  (<a class="graphic graphic_algorithm graphicRef113238" href="/d/graphic/113238.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/4303.html" rel="external">"Basic principles and technique of bronchoalveolar lavage"</a> and  <a class="medical medical_review" href="/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Cytology'</a>.)</p><p></p><p class="bulletIndent1">The finding of more than 5 percent CD-1a and CD207 positive cells on BAL strongly supports the diagnosis of PLCH  (<a class="graphic graphic_diagnosticimage graphicRef106383" href="/d/graphic/106383.html" rel="external">image 4</a>) [<a href="#rid3">3,30,56-59</a>], but is poorly sensitive. Quantitative criteria for PLCH have not been conclusively established. A finding of less than 5 percent CD-1a positive cells does <strong>not</strong> exclude the diagnosis of PLCH. Lower proportions of Langerhans-like cells can be seen in current smokers, patients with other interstitial lung disorders, and patients with minimally invasive adenocarcinoma (formerly termed bronchioloalveolar carcinoma). Therefore, the mere presence of Langerhans-like cells on BAL is of little diagnostic value.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transbronchial lung biopsy</strong> – TBLB can be sufficient to make the diagnosis in patients with nodular disease [<a href="#rid9">9,60</a>]. However, a substantial number of false negative or nondiagnostic biopsies result from sampling error and insufficient tissue with an expected yield 15 to 50 percent [<a href="#rid9">9,58-60</a>]. Multiple specimens (preferably at least six) should be obtained and examined with immunohistochemical testing for CD1a and CD207 positive cells by an expert pathologist familiar with the disease [<a href="#rid9">9</a>]. </p><p></p><p class="headingAnchor" id="H14"><span class="h2">Lung biopsy</span><span class="headingEndMark"> — </span>For most patients with symptomatic disease, but nondiagnostic findings on HRCT, BAL, and TBLB, a surgical lung biopsy, usually by video-assisted thoracoscopy, is needed to determine the diagnosis. A trial of smoking cessation prior to proceeding with surgery is a reasonable alternative in a stable patient. (See <a class="local">'Initial and supportive management'</a> below.)</p><p>In a series of 38 patients with PLCH, the diagnosis was confirmed by TBLB in 50 percent, surgical lung biopsy in 45 percent, and BAL (≥5 percent CD1a-positive Langerhans-like cells) in 5 percent [<a href="#rid58">58</a>]. A biopsy of an extrapulmonary site (skin, mandible, tongue) was positive in 11 percent. (See  <a class="medical medical_review" href="/d/html/4379.html" rel="external">"Role of lung biopsy in the diagnosis of interstitial lung disease"</a>.)</p><p class="headingAnchor" id="H1038244637"><span class="h2">Transthoracic Doppler echocardiography</span><span class="headingEndMark"> — </span>Pulmonary hypertension is a known complication of PLCH [<a href="#rid36">36,61</a>]. When pulmonary hypertension is suspected in patients with PLCH based on dyspnea or gas transfer abnormalities out of proportion to reductions in lung volumes or extent of HRCT abnormalities, we obtain echocardiography with assessment of pulmonary and right heart pressures [<a href="#rid32">32,36</a>]. Doppler echocardiogram evidence of pulmonary hypertension (ie, elevated pulmonary artery systolic pressure) needs confirmation by right heart catheterization. (See  <a class="medical medical_review" href="/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a>.)</p><p class="headingAnchor" id="H1634442235"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3518939966"><span class="h2">Diagnosis based on HRCT</span><span class="headingEndMark"> — </span>A confident clinical diagnosis can often be made on the basis of characteristic clinical presentation and high-resolution computed tomography (HRCT) showing bizarrely shaped cysts with upper lobe predominance and sparing of the costophrenic angle, ill-defined upper lobe nodules (2 to 10 mm) and preservation of lung volume  (<a class="graphic graphic_table graphicRef119828" href="/d/graphic/119828.html" rel="external">table 1</a>) [<a href="#rid59">59</a>]. In this setting, improvement in symptoms and HRCT with smoking cessation helps to solidify the diagnosis.</p><p>The finding of more than 5 percent Langerhans-like dendritic cells (CD-1a and CD207 positive) on bronchoalveolar lavage (BAL) strongly supports the diagnosis. (See <a class="local">'Flexible bronchoscopy'</a> above.) </p><p class="headingAnchor" id="H492226199"><span class="h2">Diagnosis based on lung biopsy</span><span class="headingEndMark"> — </span>A firm diagnosis of PLCH requires a lung biopsy showing characteristic peribronchial inflammatory lesions containing an admixture of Langerhans-like cells, eosinophils, lymphocytes, and neutrophils  (<a class="graphic graphic_picture graphicRef55413" href="/d/graphic/55413.html" rel="external">picture 1</a>) with associated destruction of the bronchiolar walls and adjacent lung parenchyma. Langerhans-like dendritic cells are identified by immunostaining for CD1a, CD207, and S100. (See <a class="local">'Pathology'</a> above.)</p><p>On histopathology, inflammatory lesions of PLCH surround the smaller bronchioles  (<a class="graphic graphic_picture graphicRef55413" href="/d/graphic/55413.html" rel="external">picture 1</a>) and are associated with destruction of the bronchiolar wall and adjacent lung parenchyma. The Langerhans-like dendritic cell is distinguished by pale staining cytoplasm, a large nucleus and nucleoli, and a strong presence of CD1 antigen (CD1a) on the cell surface, a feature not observed in other cells of histiocytic origin [<a href="#rid31">31</a>]. Langerin (CD207) is a transmembrane protein associated with Birbeck granules; it tends to co-associate with CD1a in LCH [<a href="#rid62">62,63</a>]. Staining for the intracellular S100 protein is less specific and can be observed in macrophages and neuroendocrine cells [<a href="#rid3">3</a>]. </p><p>Whenever possible, testing for the <em>BRAF</em> V600E and other MAPK variants is obtained, in case future targeted therapy is considered. <em>BRAF</em> expression can be assessed in biopsy samples via immunostaining [<a href="#rid10">10</a>] or by a sensitive quantitative polymerase chain reaction (PCR) test. (See <a class="local">'Somatic mutations in MAPK pathway'</a> above and  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis", section on 'Pretreatment evaluation'</a> and <a class="local">'Targeted therapy of MAPK pathway mutations'</a> below.)</p><p>On electron microscopy, which is rarely performed, Langerhans-like cells are identified by classic pentalaminar cytoplasmic inclusions or Birbeck granules (X-bodies  (<a class="graphic graphic_picture graphicRef60620" href="/d/graphic/60620.html" rel="external">picture 4</a>)).</p><p class="headingAnchor" id="H1519350598"><span class="h2">Diagnosis based on extrapulmonary LCH</span><span class="headingEndMark"> — </span>If the patient has compatible lung disease, a biopsy of extrapulmonary lesions (skin or bone) showing LCH would support the diagnosis of PLCH.</p><p>If not previously performed, a baseline fluorodeoxyglucose-positron emission tomography (FDG-PET) scan may be helpful if symptoms suggest extrapulmonary disease, but is not needed in the absence of such symptoms. (See <a class="local">'Imaging'</a> above.)</p><p class="headingAnchor" id="H1526521745"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PLCH presenting with cystic changes on high-resolution computed tomography (HRCT) includes pulmonary lymphangioleiomyomatosis, tuberous sclerosis, lymphoid interstitial pneumonia, Birt-Hogg-Dubé syndrome, and sarcoidosis  (<a class="graphic graphic_algorithm graphicRef113238" href="/d/graphic/113238.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef108810" href="/d/graphic/108810.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/112259.html" rel="external">"Diagnostic approach to the adult with cystic lung disease"</a>.)</p><p>For patients with reticular, nodular, or ground glass opacities on HRCT without cystic changes, the differential diagnosis is broad and often includes hypersensitivity pneumonitis and other idiopathic interstitial pneumonias, such as nonspecific interstitial pneumonia. (See  <a class="medical medical_review" href="/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>PLCH is usually limited to the lungs, but patients should be assessed for extrapulmonary involvement to determine whether treatment of additional sites is indicated. The evaluation of extrapulmonary LCH is described separately. (See <a class="local">'Evaluation'</a> above and  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p>All patients should be advised about smoking cessation and avoidance of smoke exposure. The optimal treatment regimen for patients with persistent and symptomatic disease has not been determined. Therapy is largely guided by expert opinion and extrapolation from experience in pediatric LCH [<a href="#rid64">64</a>].</p><p>Systemic glucocorticoid therapy may be beneficial, predominantly in patients with nodular disease. For patients who do not respond to smoking cessation or glucocorticoid therapy, the preferred choice is referral to a specialized center (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhistio.org%2F&amp;token=R9ADit2Yq2jh23FdkuMIYdp0kcdFiecjN3tBkyio%2FLA%3D&amp;TOPIC_ID=4334" target="_blank">Histiocytosis Association of America</a>) and participation in a clinical trial. If this is not possible, we suggest treatment with <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> with appropriate prophylaxis against opportunistic infection. </p><p class="headingAnchor" id="H3724146322"><span class="h2">Initial and supportive management</span><span class="headingEndMark"> — </span>The primary focus of any therapeutic regimen in patients with PLCH is cessation of tobacco smoking and avoidance of smoke exposure [<a href="#rid7">7,32,65,66</a>]. Many patients will have resolution or stabilization of disease with smoking cessation alone. Follow-up pulmonary function testing every three months in the first year after diagnosis may be useful in identifying patients who are likely to develop progressive disease [<a href="#rid1">1,25</a>]. </p><p>In a series of 40 patients, smoking cessation was the only required therapy in 25 (62 percent) [<a href="#rid5">5</a>]. We counsel patients that continued smoking increases the likelihood of progressive disease and potential for needing chemotherapy for PLCH in the future. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>Patients with chronic obstructive pulmonary disease (COPD) related to cigarette smoking or with reversibility of airflow limitation on spirometry may have symptomatic improvement with inhaled bronchodilator and, possibly, inhaled glucocorticoid therapy. (See  <a class="medical medical_review" href="/d/html/1447.html" rel="external">"Stable COPD: Initial pharmacologic management"</a>.)</p><p>Patients with dyspnea on exertion may benefit from pulmonary rehabilitation. (See  <a class="medical medical_review" href="/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p>Seasonal influenza and pneumococcal vaccination should be offered as appropriate [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.)</p><p class="headingAnchor" id="H3869542482"><span class="h2">Minimal symptoms and pulmonary function impairment</span><span class="headingEndMark"> — </span>For patients with minimal or no symptoms or pulmonary function impairment, we usually observe without specific therapy other than smoking cessation. Among 58 patients monitored for two years after initial diagnosis, 22 (38 percent) experienced worsening of at least one component of pulmonary function [<a href="#rid37">37</a>]; forced expiratory volume in one second (FEV<sub>1</sub>) and diffusing capacity for carbon monoxide (DLCO) decreased in 22 percent and forced vital capacity (FVC) worsened in 9 percent. Of note, only 20 percent quit smoking for the entire study period; complete smoking cessation would be expected to yield better stability or improvement in lung function. (See <a class="local">'Initial and supportive management'</a> above.)</p><p class="headingAnchor" id="H2627810970"><span class="h2">Progressive and symptomatic PLCH</span><span class="headingEndMark"> — </span>The optimal therapy for progressive PLCH has not been determined [<a href="#rid67">67</a>]. Patients who are still smoking require more aggressive efforts at smoking cessation. Systemic glucocorticoids have a limited role. For patients who are not candidates for or do not respond to glucocorticoids, the preferred choice is referral to a specialized center and participation in a clinical trial [<a href="#rid68">68</a>]. If this is not possible, we suggest a trial of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> with appropriate prophylaxis against opportunistic infection.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – For patients with symptomatic and progressive nodular PLCH despite smoking cessation, we suggest a trial of systemic glucocorticoids (eg, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.25 to 0.5 mg/kg per day or 30 mg/day initially with gradual tapering over six months). As evidence for improvement with glucocorticoids is limited, a reasonable alternative is not to prescribe glucocorticoids. In our experience, only patients with prominent nodular opacities respond to glucocorticoid therapy. </p><p></p><p class="bulletIndent1">Published experience with glucocorticoids is mixed [<a href="#rid25">25,28,30,31,69</a>]. In a series of 36 patients who received <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily for a mean of 9.6 months, none of the patients experienced worsening of disease, including a subset of 14 patients who had a deteriorating trend prior to prednisone [<a href="#rid28">28</a>]. However, information about smoking cessation was not provided. In a separate study of 45 patients, glucocorticoid therapy was associated with increased mortality, but this may reflect selection bias [<a href="#rid69">69</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> – Case reports have described improvement in PLCH following treatment with cladribine (2-chlorodeoxyadenosine), a chemotherapeutic agent cytotoxic for lymphocytes and monocytes, typically used in regimens for leukemia and lymphoma [<a href="#rid70">70-74</a>]. Cladribine is used (off-label) in pediatric LCH [<a href="#rid75">75</a>], but has not been formally studied in PLCH. A clinical trial in PLCH is in progress (NCT01473797; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4334" target="_blank">clinicaltrials.gov</a>). (See  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis", section on 'Relapsed or refractory disease'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> has been associated with symptomatic, radiographic, and pulmonary function improvement in adults with cystic PLCH [<a href="#rid72">72,76</a>]. Improvement in individual patients with nodular or nodulocystic disease that was refractory to <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> has also been reported with four to five cycles of cladribine at doses of 3 to 5 mg/m<sup>2 </sup>[<a href="#rid70">70,71</a>]. Cladribine can cause pancytopenia and is highly immunosuppressive, so therapy to prevent opportunistic infections with <em>Pneumocystis jirovecii</em> and herpes viruses (eg, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>) is advised [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> – Cytarabine, a nucleoside (pyrimidine) analogue that inhibits DNA synthesis, is used in treatment regimens for myeloid leukemias. Cytarabine is used in adults with multiple bone or other noncutaneous lesions (100 mg/m<sup>2</sup> intravenously, daily for five days, repeated monthly for 12 months). It is also used alone or in combination regimens in pediatric LCH with high rates of clinical response. (See  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">Vinblastine</a> – Vinblastine, which is a successful therapy in pediatric LCH, was examined in 35 patients with LCH of whom 17 had lung involvement [<a href="#rid77">77</a>]. While extrapulmonary manifestations improved, pulmonary function did not. We do not use this agent in patients with PLCH in the absence of extrapulmonary LCH. (See  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation therapy can be used to treat symptomatic bone lesions, but it is not useful in treatment of PLCH.</p><p></p><p class="headingAnchor" id="H1979655562"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>For patients with pulmonary hypertension (PH) complicating PLCH (ie, mean pulmonary artery pressure is &gt;20 mmHg at rest, measured by right heart catheterization), we suggest referral to a specialized center with experience treating PH and advanced lung disease. Supportive measures for PH include oxygen and diuretics, when indicated, and routine supportive measures as described above. (See <a class="local">'Initial and supportive management'</a> above and  <a class="medical medical_review" href="/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a> and  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a>.)</p><p>The role of PH-targeted therapy in PH complicating PLCH is not well-established, but benefit has been described in a small number of patients [<a href="#rid36">36,78,79</a>]. In a series of 12 patients with pulmonary hypertension complicating PLCH, therapy with an endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostanoid (<a class="drug drug_general" data-topicid="8895" href="/d/drug information/8895.html" rel="external">iloprost</a>), or a combination led to modest improvements in mean pulmonary arterial pressure (from 56 ± 14 to 45 ± 12 mmHg) and pulmonary vascular resistance (from 701 ± 239 to 469 ± 210 dynes-sec-cm<sup>-5</sup>) between baseline and follow up evaluations [<a href="#rid36">36</a>]. No significant worsening of oxygenation was observed with treatment. However, caution is advised as pulmonary arterial hypertension-directed therapy can exacerbate ventilation-perfusion abnormalities and worsen gas exchange in patients with parenchymal lung disease. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis", section on 'Our approach'</a>.)</p><p class="headingAnchor" id="H649340599"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>For patients with progressive disease despite the above interventions, we prefer the option of treatment in the context of a clinical trial. Targeted therapy directed at mitogen-activated protein kinase (MAPK) pathway mutations is appealing, but needs rigorous assessment due to the high potential for adverse effects. Patients with advanced lung disease may be candidates for lung transplantation.</p><p class="headingAnchor" id="H3730863547"><span class="h3">Clinical trials</span><span class="headingEndMark"> — </span>Clinical trials of therapy for LCH are ongoing, and enrollment may be appropriate for selected patients. In the United States, the Histiocyte Society initiated a series of protocols for treatment of adults with LCH in 2001. Treatment protocols and other information can be obtained through the Histiocytosis Association of America (1-800-548-2758 or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhistio.org%2F&amp;token=R9ADit2Yq2jh23FdkuMIYdp0kcdFiecjN3tBkyio%2FLA%3D&amp;TOPIC_ID=4334" target="_blank">www.histio.org</a>) and at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4334" target="_blank">https://www.clinicaltrials.gov/</a>. (See  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis"</a>.)</p><p class="headingAnchor" id="H3623945190"><span class="h3">Targeted therapy of MAPK pathway mutations</span><span class="headingEndMark"> — </span>Identification of somatic mutations in the MAPK pathway, such as <em>BRAF</em> V600E and MAPK2K1, in patients with PLCH has led to the proposal of using targeted therapy with agents such as <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, or <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> [<a href="#rid10">10,21,80</a>]. In case reports, these agents have led to clinical response in patients with refractory or relapsed LCH, but recurrent disease was reported after cessation of therapy. (See  <a class="medical medical_review" href="/d/html/16627.html" rel="external">"Treatment of non-pulmonary Langerhans cell histiocytosis", section on 'Relapsed or refractory disease'</a>.)</p><p>The role of specific inhibitor drugs in PLCH remains to be defined [<a href="#rid32">32,81</a>]. </p><p><a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">Vemurafenib</a> is approved in the United States for treatment of symptomatic patients with Erdheim–Chester disease (a related non-Langerhans cell histiocytic myeloid neoplasm) and the <em>BRAF</em> V600E variant. (See  <a class="medical medical_review" href="/d/html/13942.html" rel="external">"Erdheim-Chester disease", section on 'BRAF inhibition'</a>.)</p><p class="headingAnchor" id="H2771273781"><span class="h3">Lung transplantation</span><span class="headingEndMark"> — </span>Lung transplantation is an option for patients with advanced, progressive lung disease unless contraindications are present [<a href="#rid5">5,82</a>]. In a series of 40 patients who underwent single or bilateral lung transplantation for advanced PLCH, survival was 77 percent at one year and 54 percent at 10 years [<a href="#rid82">82</a>]. Recurrence of PLCH in the transplanted lung is reported in approximately 10 percent, but it is unclear if this affects overall post-transplant survival [<a href="#rid5">5,82-84</a>]. Preoperative extrapulmonary LCH is a risk factor for recurrence [<a href="#rid82">82</a>].</p><p>General information about lung transplantation and guidelines for patient selection are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a> and  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a>.)</p><p class="headingAnchor" id="H461157443"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Complications of PLCH include pneumothorax, hemoptysis, and pulmonary vascular disease. Extrapulmonary manifestations of PLCH are described above. (See <a class="local">'Extrapulmonary manifestations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumothorax</strong> – Recurrent spontaneous pneumothorax occurs in 10 to 25 percent of patients [<a href="#rid29">29,85</a>]. Pleural thickening or effusion is rarely seen in the absence of a previous pneumothorax. (See <a class="local">'Symptoms and signs'</a> above.)</p><p></p><p class="bulletIndent1">The management of spontaneous pneumothorax in PLCH follows that for spontaneous secondary pneumothorax and, in general, includes pleurodesis. For patients who require surgical intervention, a lung biopsy at the time of the procedure can secure the diagnosis. (See  <a class="medical medical_review" href="/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary vascular disease</strong> – Pulmonary arteriopathy and veno-occlusive disease can occur independently from parenchymal and airway disease, and can impair diffusing capacity and exercise capacity to a degree disproportionate to radiographic findings [<a href="#rid36">36,61,86-88</a>]. (See  <a class="medical medical_review" href="/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a> and  <a class="medical medical_review" href="/d/html/8269.html" rel="external">"Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis in adults"</a>.)</p><p></p><p class="bulletIndent1">Pulmonary hypertension can be present even in the absence of overt symptoms of right heart failure. An echocardiographic study of patients with histologically proven PLCH noted a resting peak pulmonary artery pressure ≥35 mmHg in 15 of 17 patients (88 percent) [<a href="#rid61">61</a>]. The development of pulmonary hypertension was strongly associated with increased mortality, suggesting that severe pulmonary hypertension is not limited to patients with end-stage cystic lung disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemoptysis</strong> – Hemoptysis is occasionally reported (13 percent), but should prompt consideration of superimposed infection (eg, Aspergillus) or tumor [<a href="#rid35">35,89</a>]. (See  <a class="medical medical_review" href="/d/html/4333.html" rel="external">"Evaluation of nonlife-threatening hemoptysis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign and malignant tumors</strong> – A number of malignant and nonmalignant tumors have been found in association with PLCH [<a href="#rid90">90-94</a>]. These include bronchogenic carcinoma (5 percent of patients) [<a href="#rid25">25,29,91,95</a>], Hodgkin and non-Hodgkin lymphoma [<a href="#rid94">94,96</a>], pulmonary carcinoid tumor, and mediastinal ganglioneuroma. The malignancy may precede, follow, or occur concomitantly with the diagnosis of PLCH. The carcinogenic effect of cigarette smoke may contribute to development of some of these tumors, but the lung cancer incidence is likely higher than expected for age and smoking history [<a href="#rid29">29</a>]. </p><p></p><p class="headingAnchor" id="H16"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The overall survival for PLCH is good, with a large prospective cohort indicating a 10-year survival of &gt;90 percent [<a href="#rid29">29</a>]. However, the natural history of PLCH is variable, with some patients experiencing spontaneous remission of symptoms and others (approximately 5 percent) progressing to end-stage fibrotic lung disease  (<a class="graphic graphic_figure graphicRef71979" href="/d/graphic/71979.html" rel="external">figure 2</a>) [<a href="#rid29">29,37</a>]. </p><p>Both smoking status and the radiographic picture can affect disease progression. Most subjects demonstrate gradual progression with continued cigarette smoking, while the disease may regress with the cessation of smoking [<a href="#rid65">65</a>]. Patients with radiographic sparing of the costophrenic angle are more likely to remain stable or improve compared to those with costophrenic angle involvement [<a href="#rid42">42</a>]. Pulmonary hypertension is common with advanced disease, and is independently associated with decreased survival [<a href="#rid61">61</a>]. The prognosis of PLCH does not appear to be influenced by the specific MAPK variant [<a href="#rid19">19</a>]. (See <a class="local">'Somatic mutations in MAPK pathway'</a> above.)</p><p>Despite the overall good prognosis of PLCH, a minority of patients will develop end stage lung disease or malignancy. In a large prospective cohort of 206 patients with pulmonary LCH, the 5- and 10-year survival were 94 and 93 percent, respectively, after a median 5.1 years of follow-up [<a href="#rid29">29</a>]. This survival was shorter than age-matched controls from the general population  (<a class="graphic graphic_figure graphicRef139118" href="/d/graphic/139118.html" rel="external">figure 3</a>), but longer than that seen in prior retrospective studies [<a href="#rid25">25,36,69,97</a>], possibly due to increasing early detection by high-resolution computed tomography (HRCT) and selective referral of later stage patients in previous studies. Half (6 of 12) of the deaths that occurred during the follow-up period were associated with respiratory failure and pulmonary hypertension; nearly half (5 of 12) were associated with malignancy. </p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition, pathogenesis, and histopathology</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary Langerhans cell histiocytosis (PLCH) is an uncommon cystic-interstitial lung disease that primarily affects young adult smokers. The pathologic cell of PLCH is a Langerhans-like dendritic cell that is a differentiated cell of the monocyte-macrophage line with CD1a, S100 protein, and langerin (CD207) expressed on the cell surface. These cells virtually always carry mutations in the mitogen-activated protein kinase (MAPK) pathway, most commonly <em>BRAF</em> V600E. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In PLCH, lung lesions frequently extend widely into the parenchyma surrounding the bronchovascular structures, producing the so-called stellate lesions that are characteristic of this disorder  (<a class="graphic graphic_picture graphicRef52774 graphicRef71884 graphicRef51661" href="/d/graphic/52774.html" rel="external">picture 3A-C</a>). (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients can present with a spontaneous pneumothorax, an abnormal chest radiograph obtained for another reason, or a nonproductive cough, dyspnea, or constitutional symptoms, especially fever or weight loss. Recurrent spontaneous pneumothorax occurs in 15 to 25 percent of patients. The physical examination is usually normal. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-resolution computed tomography (HRCT) findings can range from reticular opacities to nodules (2 to 10 mm) to cysts, or more typically a combination of multiple cysts and nodules, with a mid to upper zone predominance  (<a class="graphic graphic_table graphicRef119828" href="/d/graphic/119828.html" rel="external">table 1</a>). The combination of nodules and cysts in the upper lung zones in a young smoker is so characteristic that it can be diagnostic of PLCH  (<a class="graphic graphic_diagnosticimage graphicRef58182 graphicRef69891 graphicRef72698" href="/d/graphic/58182.html" rel="external">image 3A-C</a>). (See <a class="local">'Imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Flexible bronchoscopy with bronchoalveolar lavage (BAL) and usually transbronchial lung biopsy (TBLB) is performed in most patients to look for CD1a-positive Langerhans-like cells and evaluate for other causes of nodular or cystic disease  (<a class="graphic graphic_algorithm graphicRef113238" href="/d/graphic/113238.html" rel="external">algorithm 1</a>). The finding of more than 5 percent Langerhans-like cells (CD-1a and CD207 positive) on BAL or typical clusters of Langerhans-like cells on TBLB strongly suggests the diagnosis of PLCH  (<a class="graphic graphic_diagnosticimage graphicRef106383" href="/d/graphic/106383.html" rel="external">image 4</a>), but is poorly sensitive. (See <a class="local">'Flexible bronchoscopy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the HRCT and BAL are not sufficiently diagnostic, a surgical lung biopsy is often needed to confirm the diagnosis and exclude other causes of nodular or cystic lung disease. Alternatively, for patients with minimal or no symptoms or respiratory impairment, a trial of smoking cessation with follow-up assessment and imaging in three months may be reasonable. (See <a class="local">'Lung biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The primary focus in all patients with PLCH is cessation of smoking and avoidance of smoke exposure. Approximately 60 percent of patients will improve with this intervention alone. (See <a class="local">'Initial and supportive management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with progressive, nodular PLCH who remain symptomatic despite smoking cessation, we suggest a trial of systemic glucocorticoid therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The usual initial dose is the equivalent of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 0.25 to 0.5 mg/kg per day or 30 mg/day, with gradual tapering over six months. (See <a class="local">'Progressive and symptomatic PLCH'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are not candidates for or do not respond to glucocorticoids, the preferred choice is referral to a specialized center (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhistio.org%2F&amp;token=R9ADit2Yq2jh23FdkuMIYdp0kcdFiecjN3tBkyio%2FLA%3D&amp;TOPIC_ID=4334" target="_blank">Histiocytosis Association of America</a>) and participation in a clinical trial. If this is not possible, we suggest a trial of <a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">cladribine</a> or <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> with appropriate monitoring of peripheral blood for cytopenia and prophylaxis against opportunistic infection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Progressive and symptomatic PLCH'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lung transplantation is an option for patients with advanced PLCH in the absence of other contraindications. Recurrence of PLCH in the allograft is reported, particularly in patients with multisystemic LCH, but may not affect survival. (See <a class="local">'Lung transplantation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Information about clinical trials for patients with PLCH can be obtained at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhistio.org%2F&amp;token=R9ADit2Yq2jh23FdkuMIYdp0kcdFiecjN3tBkyio%2FLA%3D&amp;TOPIC_ID=4334" target="_blank">www.histio.org</a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4334" target="_blank">https://www.clinicaltrials.gov/</a>. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med 2004; 25:561.</a></li><li><a class="nounderline abstract_t">Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest 2003; 123:1673.</a></li><li><a class="nounderline abstract_t">Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006; 27:1272.</a></li><li><a class="nounderline abstract_t">Wei P, Lu HW, Jiang S, et al. Pulmonary langerhans cell histiocytosis: case series and literature review. Medicine (Baltimore) 2014; 93:e141.</a></li><li><a class="nounderline abstract_t">Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med 2015; 26:351.</a></li><li><a class="nounderline abstract_t">Watanabe R, Tatsumi K, Hashimoto S, et al. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med 2001; 40:998.</a></li><li class="breakAll">Vassallo R, Limper AH, Ryu JH. Smoking-related interstitial lung disease. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT, USA 2011. p.961.</li><li><a class="nounderline abstract_t">Thomeer M, Demedts M, Vandeurzen K, VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001; 56:163.</a></li><li><a class="nounderline abstract_t">Roden AC, Yi ES. Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective. Arch Pathol Lab Med 2016; 140:230.</a></li><li><a class="nounderline abstract_t">Roden AC, Hu X, Kip S, et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 2014; 38:548.</a></li><li><a class="nounderline abstract_t">Brown NA, Elenitoba-Johnson KSJ. Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis. Curr Opin Pulm Med 2018; 24:281.</a></li><li><a class="nounderline abstract_t">Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184:4557.</a></li><li><a class="nounderline abstract_t">Casolaro MA, Bernaudin JF, Saltini C, et al. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137:406.</a></li><li><a class="nounderline abstract_t">Soler P, Moreau A, Basset F, Hance AJ. Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells. Am Rev Respir Dis 1989; 139:1112.</a></li><li><a class="nounderline abstract_t">Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118:811.</a></li><li><a class="nounderline abstract_t">Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993; 17:971.</a></li><li><a class="nounderline abstract_t">Vassallo R, Jensen EA, Colby TV, et al. The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations. Chest 2003; 124:1199.</a></li><li><a class="nounderline abstract_t">Fukuda Y, Basset F, Soler P, et al. Intraluminal fibrosis and elastic fiber degradation lead to lung remodeling in pulmonary Langerhans cell granulomatosis (histiocytosis X). Am J Pathol 1990; 137:415.</a></li><li><a class="nounderline abstract_t">Jouenne F, Chevret S, Bugnet E, et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013; 143:1679.</a></li><li><a class="nounderline abstract_t">Mourah S, How-Kit A, Meignin V, et al. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J 2016; 47:1785.</a></li><li><a class="nounderline abstract_t">Zhang L, Pacheco-Rodriguez G, Steagall WK, et al. BRAF and NRAS mutations in circulating Langerhans-like CD1a+ cells in a patient with pulmonary Langerhans' cell histiocytosis. Eur Respir J 2017; 50.</a></li><li><a class="nounderline abstract_t">Schönfeld N, Dirks K, Costabel U, et al. A prospective clinical multicentre study on adult pulmonary Langerhans' cell histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:132.</a></li><li><a class="nounderline abstract_t">Gómez-Román J, Zarrabeitia MT, Santurtún A, et al. Pulmonary Langerhans cell histiocytosis "de novo" after lung transplantation. Pathol Int 2017; 67:632.</a></li><li><a class="nounderline abstract_t">Vassallo R, Ryu JH, Schroeder DR, et al. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002; 346:484.</a></li><li><a class="nounderline abstract_t">Götz G, Fichter J. Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res 2004; 9:510.</a></li><li><a class="nounderline abstract_t">Mason RH, Foley NM, Branley HM, et al. Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register. Thorax 2014; 69:766.</a></li><li><a class="nounderline abstract_t">Schönfeld N, Frank W, Wenig S, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993; 60:38.</a></li><li><a class="nounderline abstract_t">Benattia A, Bugnet E, Walter-Petrich A, et al. Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort. Eur Respir J 2022; 59.</a></li><li><a class="nounderline abstract_t">Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000; 55:405.</a></li><li><a class="nounderline abstract_t">Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000; 342:1969.</a></li><li><a class="nounderline abstract_t">Lorillon G, Tazi A. How I manage pulmonary Langerhans cell histiocytosis. Eur Respir Rev 2017; 26.</a></li><li><a class="nounderline abstract_t">Radzikowska E, Błasińska-Przerwa K, Wiatr E, et al. Pneumothorax in Patients with Pulmonary Langerhans Cell Histiocytosis. Lung 2018; 196:715.</a></li><li><a class="nounderline abstract_t">Marcy TW, Reynolds HY. Pulmonary histiocytosis X. Lung 1985; 163:129.</a></li><li><a class="nounderline abstract_t">Crausman RS, Jennings CA, Tuder RM, et al. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153:426.</a></li><li><a class="nounderline abstract_t">Le Pavec J, Lorillon G, Jaïs X, et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142:1150.</a></li><li><a class="nounderline abstract_t">Tazi A, de Margerie C, Naccache JM, et al. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis 2015; 10:30.</a></li><li><a class="nounderline abstract_t">Epler GR, Carrington CB, Gaensler EA. Crackles (rales) in the interstitial pulmonary diseases. Chest 1978; 73:333.</a></li><li><a class="nounderline abstract_t">Gupta N, Langenderfer D, McCormack FX, et al. Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective. Ann Am Thorac Soc 2017; 14:17.</a></li><li><a class="nounderline abstract_t">Aguayo SM, Schwarz MI, Mortenson RL. The role of the chest radiograph in the evaluation of disease severity and clinical course in eosinophilic granuloma. Am Rev Respir Dis 1990; 141:A61.</a></li><li><a class="nounderline abstract_t">Kulwiec EL, Lynch DA, Aguayo SM, et al. Imaging of pulmonary histiocytosis X. Radiographics 1992; 12:515.</a></li><li><a class="nounderline abstract_t">Lacronique J, Roth C, Battesti JP, et al. Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases. Thorax 1982; 37:104.</a></li><li><a class="nounderline abstract_t">Castoldi MC, Verrioli A, De Juli E, Vanzulli A. Pulmonary Langerhans cell histiocytosis: the many faces of presentation at initial CT scan. Insights Imaging 2014; 5:483.</a></li><li><a class="nounderline abstract_t">Kim HJ, Lee KS, Johkoh T, et al. Pulmonary Langerhans cell histiocytosis in adults: high-resolution CT-pathology comparisons and evolutional changes at CT. Eur Radiol 2011; 21:1406.</a></li><li><a class="nounderline abstract_t">Brauner MW, Grenier P, Tijani K, et al. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology 1997; 204:497.</a></li><li><a class="nounderline abstract_t">Canuet M, Kessler R, Jeung MY, et al. Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration 2007; 74:640.</a></li><li><a class="nounderline abstract_t">Tazi A, Marc K, Dominique S, et al. Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis. Eur Respir J 2012; 40:905.</a></li><li><a class="nounderline abstract_t">Krajicek BJ, Ryu JH, Hartman TE, et al. Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest 2009; 135:1542.</a></li><li><a class="nounderline abstract_t">Jessop S, Crudgington D, London K, et al. FDG PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 2020; 67:e28034.</a></li><li><a class="nounderline abstract_t">Obert J, Vercellino L, Van Der Gucht A, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis. Eur J Nucl Med Mol Imaging 2017; 44:598.</a></li><li><a class="nounderline abstract_t">Chusid, EL. Pulmonary eosinophilic granuloma: aspects of pulmonary function. Mt Sinai J Med 1961; 33:116.</a></li><li><a class="nounderline abstract_t">Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981; 60:385.</a></li><li><a class="nounderline abstract_t">HOFFMAN L, COHN JE, GAENSLER EA. Respiratory abnormalities in eosinophilic granuloma of the lung. Longterm study of five cases. N Engl J Med 1962; 267:577.</a></li><li><a class="nounderline abstract_t">Rolland-Debord C, Fry S, Giovannelli J, et al. Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis. PLoS One 2017; 12:e0170035.</a></li><li class="breakAll">King TE Jr. Bronchoscopy in interstitial lung disease. In: Textbook of Bronchoscopy, Feinsilver SH, Fein AM (Eds), Williams &amp; Wilkins, Baltimore 1995. p.185.</li><li><a class="nounderline abstract_t">Harari S, Comel A. Pulmonary Langerhans cell Histiocytosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18:253.</a></li><li><a class="nounderline abstract_t">Auerswald U, Barth J, Magnussen H. Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991; 169:305.</a></li><li><a class="nounderline abstract_t">Baqir M, Vassallo R, Maldonado F, et al. Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis. J Bronchology Interv Pulmonol 2013; 20:309.</a></li><li><a class="nounderline abstract_t">Harari S, Torre O, Cassandro R, et al. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 2012; 106:1286.</a></li><li><a class="nounderline abstract_t">Housini I, Tomashefski JF Jr, Cohen A, et al. Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy. Arch Pathol Lab Med 1994; 118:523.</a></li><li><a class="nounderline abstract_t">Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79:1269.</a></li><li><a class="nounderline abstract_t">Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol 2008; 32:615.</a></li><li><a class="nounderline abstract_t">Xu X, Liu WP, Yang QP, et al. [Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical analysis of 258 cases]. Zhonghua Bing Li Xue Za Zhi 2012; 41:91.</a></li><li><a class="nounderline abstract_t">Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013; 8:72.</a></li><li><a class="nounderline abstract_t">Mogulkoc N, Veral A, Bishop PW, et al. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999; 115:1452.</a></li><li><a class="nounderline abstract_t">Kinoshita Y, Watanabe K, Sakamoto A, Hidaka K. Pulmonary Langerhans Cell Histiocytosis-associated Pulmonary Hypertension Showing a Drastic Improvement Following Smoking Cessation. Intern Med 2016; 55:491.</a></li><li><a class="nounderline abstract_t">Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax 2017; 72:937.</a></li><li class="breakAll">Histiocytosis Association of America. https://www.histio.org (Accessed on October 29, 2018).</li><li><a class="nounderline abstract_t">Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J 1996; 9:2002.</a></li><li><a class="nounderline abstract_t">Lazor R, Etienne-Mastroianni B, Khouatra C, et al. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax 2009; 64:274.</a></li><li><a class="nounderline abstract_t">Aerni MR, Aubry MC, Myers JL, Vassallo R. Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker. Respir Med 2008; 102:316.</a></li><li><a class="nounderline abstract_t">Lorillon G, Bergeron A, Detourmignies L, et al. Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2012; 186:930.</a></li><li><a class="nounderline abstract_t">Epaud R, Ducou Le Pointe H, Fasola S, et al. Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. Eur Respir J 2015; 45:831.</a></li><li><a class="nounderline abstract_t">Grobost V, Khouatra C, Lazor R, et al. Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. Orphanet J Rare Dis 2014; 9:191.</a></li><li><a class="nounderline abstract_t">Néel A, Artifoni M, Fontenoy AM, et al. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol 2020; 189:869.</a></li><li><a class="nounderline abstract_t">Nasser M, Traclet J, Cottin V. Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis. ERJ Open Res 2018; 4.</a></li><li><a class="nounderline abstract_t">Tazi A, Lorillon G, Haroche J, et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis 2017; 12:95.</a></li><li><a class="nounderline abstract_t">May A, Kane G, Yi E, et al. Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy. Respir Med Case Rep 2015; 14:13.</a></li><li><a class="nounderline abstract_t">Fukuda Y, Miura S, Fujimi K, et al. Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension. Eur J Prev Cardiol 2014; 21:1481.</a></li><li><a class="nounderline abstract_t">Lin HT, Wikenheiser-Brokamp KA, Udstuen G, et al. Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy. Chest 2023; 163:e53.</a></li><li><a class="nounderline abstract_t">Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med 2015; 373:726.</a></li><li><a class="nounderline abstract_t">Dauriat G, Mal H, Thabut G, et al. Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81:746.</a></li><li><a class="nounderline abstract_t">Gabbay E, Dark JH, Ashcroft T, et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53:326.</a></li><li><a class="nounderline abstract_t">Habib SB, Congleton J, Carr D, et al. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation. Thorax 1998; 53:323.</a></li><li><a class="nounderline abstract_t">Mendez JL, Nadrous HF, Vassallo R, et al. Pneumothorax in pulmonary Langerhans cell histiocytosis. Chest 2004; 125:1028.</a></li><li><a class="nounderline abstract_t">Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161:216.</a></li><li><a class="nounderline abstract_t">Taniyama D, Kamata H, Miyamoto K, et al. Autopsy Findings in A Case of Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. Am J Case Rep 2017; 18:1401.</a></li><li><a class="nounderline abstract_t">Hamada K, Teramoto S, Narita N, et al. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15:421.</a></li><li><a class="nounderline abstract_t">Knight RK. Haemoptysis in eosinophilic granuloma. Br J Dis Chest 1979; 73:181.</a></li><li><a class="nounderline abstract_t">Lombard CM, Medeiros LJ, Colby TV. Pulmonary histiocytosis X and carcinoma. Arch Pathol Lab Med 1987; 111:339.</a></li><li><a class="nounderline abstract_t">Sadoun D, Vaylet F, Valeyre D, et al. Bronchogenic carcinoma in patients with pulmonary histiocytosis X. Chest 1992; 101:1610.</a></li><li><a class="nounderline abstract_t">Tomashefski JF, Khiyami A, Kleinerman J. Neoplasms associated with pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1991; 115:499.</a></li><li><a class="nounderline abstract_t">Tsuji T, Nakamura S, Tanaka M. Pulmonary Langerhans cell histiocytosis associated with lingual carcinoma. Intern Med 2004; 43:713.</a></li><li><a class="nounderline abstract_t">Coli A, Bigotti G, Ferrone S. Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies. Virchows Arch A Pathol Anat Histopathol 1991; 418:369.</a></li><li><a class="nounderline abstract_t">Uskul BT, Turker H, Bayraktar OU, Onemli M. Bronchogenic carcinoma developing during a long-term course of pulmonary Langerhans' cell histiocytosis. Intern Med 2009; 48:359.</a></li><li><a class="nounderline abstract_t">Feuillet S, Louis L, Bergeron A, et al. Pulmonary Langerhans cell histiocytosis associated with Hodgkin's lymphoma. Eur Respir Rev 2010; 19:86.</a></li><li><a class="nounderline abstract_t">Aricò M, Girschikofsky M, Généreau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003; 39:2341.</a></li></ol></div><div id="topicVersionRevision">Topic 4334 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15331192" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12740289" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772390" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adult pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415669" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pulmonary langerhans cell histiocytosis: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899682" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688843" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinico-epidemiological features of pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11688843" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinico-epidemiological features of pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11484513" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26927717" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pulmonary Langerhans Cell Histiocytosis: An Update From the Pathologists' Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24625419" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29470255" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20220088" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277501" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2712439" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cigarette smoking-induced changes in the number and differentiated state of pulmonary dendritic cells/Langerhans cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/310647" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8372949" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14555547" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis: high-resolution CT, histologic, and functional correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386203" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Intraluminal fibrosis and elastic fiber degradation lead to lung remodeling in pulmonary Langerhans cell granulomatosis (histiocytosis X).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31806714" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287985" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076591" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025887" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : BRAF and NRAS mutations in circulating Langerhans-like CD1a+ cells in a patient with pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461076" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A prospective clinical multicentre study on adult pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29052290" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pulmonary Langerhans cell histiocytosis "de novo" after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844849" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15649860" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Langerhans'-cell histiocytosis in 58 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482091" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary Langerhans cell histiocytosis (PLCH): a new UK register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469818" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34675043" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term outcomes of adult pulmonary Langerhans cell histiocytosis: a prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770823" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adult pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877650" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary Langerhans'-cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28877978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : How I manage pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30187131" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pneumothorax in Patients with Pulmonary Langerhans Cell Histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3930893" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8542154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459770" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887097" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/630930" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Crackles (rales) in the interstitial pulmonary diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737563" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The role of the chest radiograph in the evaluation of disease severity and clinical course in eosinophilic granuloma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1609142" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Imaging of pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979115" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chest radiological features of pulmonary histiocytosis X: a report based on 50 adult cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996395" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pulmonary Langerhans cell histiocytosis: the many faces of presentation at initial CT scan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21311888" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pulmonary Langerhans cell histiocytosis in adults: high-resolution CT-pathology comparisons and evolutional changes at CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240543" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675829" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441752" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Serial computed tomography and lung function testing in pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447918" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31599488" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : FDG PET-CT in pediatric Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27645693" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : 18F-fluorodeoxyglucose positron emission tomography-computed tomography in the management of adult multisystem Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pulmonary eosinophilic granuloma: aspects of pulmonary function</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6975871" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14042305" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Respiratory abnormalities in eosinophilic granuloma of the lung. Longterm study of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072848" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28072848" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Physiologic Determinants of Exercise Capacity in Pulmonary Langerhans Cell Histiocytosis: A Multidimensional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587096" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pulmonary Langerhans cell Histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1758200" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24162113" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Utility of bronchoscopy in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22770823" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7514863" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Transbronchial biopsy in patients with pulmonary eosinophilic granuloma. Comparison with findings on open lung biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15473409" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18277880" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455884" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : [Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical analysis of 258 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23672541" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334170" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26935369" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pulmonary Langerhans Cell Histiocytosis-associated Pulmonary Hypertension Showing a Drastic Improvement Following Smoking Cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28689173" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Current understanding and management of pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28689173" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Current understanding and management of pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8902457" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Sociétéde Pathologie Thoracique du Nord.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252036" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935961" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118088" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cladribine is effective against cystic pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25395031" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cladribine improves lung cysts and pulmonary function in a child with histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25433492" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191819" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29492406" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28532436" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26029568" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897898" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36759117" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Marked Improvement in Soft Tissue and CNS Manifestations of Adult Langerhans Cell Histiocytosis on Targeted MEK Inhibitor Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26287849" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534477" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9741381" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Recurrence of Langerhans' cell granulomatosis following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9741380" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15006964" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pneumothorax in pulmonary Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619823" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Severe pulmonary hypertension in histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29301140" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Autopsy Findings in A Case of Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706515" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/394756" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Haemoptysis in eosinophilic granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3493752" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pulmonary histiocytosis X and carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1600781" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Bronchogenic carcinoma in patients with pulmonary histiocytosis X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2021319" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Neoplasms associated with pulmonary eosinophilic granuloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15468972" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pulmonary Langerhans cell histiocytosis associated with lingual carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1708928" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Histiocytosis X arising in Hodgkin's disease: immunophenotypic characterization with a panel of monoclonal antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19252362" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Bronchogenic carcinoma developing during a long-term course of pulmonary Langerhans' cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956172" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pulmonary Langerhans cell histiocytosis associated with Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14556926" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
